Heterogeneity of response to lipid-lowering therapy  by Bach, Richard G.
median number of syncopal events dropped in both groups during
the follow-up (from 3 to 2 and 0), simply after evaluating them,
performing the tilt table test and explaining the pathogenesis of the
disease. This fact may explain Dr. Sra’s (2) skepticism on the
medical capacity to prove the benefit of any treatment for vasovagal
syncope. This could also be the reason why almost any treatment
that has been tested for the therapy of vasovagal syncope has been
considered to be effective (3). But we do not know whether a
clinical diagnosis, reassuring the patient and explaining to the
patient the postural maneuvers can be enough to provide symp-
tomatic relief in most patients.
We would like to congratulate Sheldon et al. for his efforts in
establishing the role of beta-blockers for the treatment of vasovagal
syncope. We share his frustrations in the treatment of this
disabling and frequent disease. There is no doubt that new
randomized and controlled studies are needed to reach a definitive
answer. We are happy to have raised doubts on the efficacy of the
drugs most commonly used for this pathology.
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Heterogeneity of Response
to Lipid-Lowering Therapy
I read with great interest the article by Penny et al. (1) on changes
in endothelium-dependent vasomotor responses in mildly diseased
coronary arteries after lipid-lowering therapy. In that report, the
investigators studied angiographic responses to acetylcholine (Ach)
along successive 3-mm coronary segments. On average there was a
small improvement in vasoresponsiveness to Ach after lipid-
lowering therapy. Changes in responsiveness correlated with a
marker of oxidized low-density lipoprotein (LDL), but not with
LDL or total cholesterol levels. As the title implies, the researchers
concluded that, overall, lipid-lowering drug treatment reverses
coronary endothelial dysfunction.
Although the reported observations generally support the broad
concept that, on average, lipid lowering in hypercholesterolemic
individuals with atherosclerotic disease can improve endothelial
function, they also appear to suggest a potentially important
additional and perhaps counterintuitive hypothesis: that the coro-
nary vasomotor responses of some patients may actually react
adversely to lipid-lowering therapy. Reiterating the original obser-
vations of El-Tamimi et al. (2), who showed adjacent segments in
the same artery can show vasodilatory and vasoconstrictive re-
sponses, the investigators document an extraordinary heterogeneity
in responses of individual coronary segments to Ach, both at
baseline and after treatment. More remarkable, the changes in
intraindividual coronary artery segment responses after therapy
appear to occur in both directions, with a large number of
segments showing a decline in vasodilation or vasoconstriction at
follow-up. Though the majority of the “most constricted” seg-
ments at baseline demonstrated improved responses at follow-up,
only 4 of the 29 patients showed arteries that lacked some
segmental “deterioration” in function. Judging from Figure 3 in the
Penny et al. (1) study, where individual segment response changes
were plotted, it appears that 40% to 45% of patients showed a
predominantly contrarian response, with more segments showing a
decline in vasomotor responsiveness rather than “improvement.”
Whereas this may represent regression to the mean, the mecha-
nism is unclear. Although the graphical expression of the data
suggests moderation of responses at follow-up, it leaves some
ambiguity with respect to the severity of the deteriorated segmental
responses, and it seems possible that the magnitude of the
heterogeneity may have been underestimated by the methods
employed.
The benefits of lipid-lowering therapy for reducing clinical
events in patients with hypercholesterolemia and coronary artery
disease have been well established. The observations by Penny et
al. (1), as well as the results of the Coronary Artery Reactivity
After Treatment with Simvastatin (CARATS) trial (3), which
failed to show significant improvement in endothelium-dependent
coronary vasomotor and blood flow responses in patients treated
for six months with simvistatin, highlight a degree of complexity
and inter- and intraindividual variability of response to statin
and/or lipid-lowering therapy that is currently poorly understood,
and yet is one that raises important questions. Are these hetero-
geneous responses the result of random variability, or do the data
imply that there is a subgroup of patients whose coronaries may
respond poorly or even adversely to lipid-lowering therapy? Be-
cause the investigators have demonstrated a correlation between
changes in responsiveness and levels of circulating oxidized LDL
(which are not reliably reduced by statin therapy [4]), do the results
imply that oxidized LDL levels may help identify those patients
who are unlikely to show improvement in endothelial function
with lipid-lowering therapy alone, and may need more aggressive
additional treatment? Would the clinical benefit of statin therapy
be greater if we could select likely patient/coronary “responders”
from “nonresponders” or worse, “adverse responders”? Given that
multiple mechanisms may be involved in the benefit of statin
therapy, this interpretation might be overly simplistic. Neverthe-
less, the observations of Penny et al. (1) suggest variability in
coronary responses to lipid-lowering therapy that may be clinically
relevant and warrant further investigation.
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REPLY
We appreciate Dr. Bach’s interesting comments regarding our
study of the changes in coronary endothelial dysfunction occurring
after lipid lowering (1). We certainly agree that the segmental
heterogeneity of these changes in response to acetlycholine sug-
gests a level of complexity that has been previously underempha-
sized.
The reduction in clinical events in groups of patients on
lipid-lowering therapy is irrefutable. Our work confirms previous
reports that this therapy can also improve endothelial function in
a group of patients. However, as in all therapies, not all patients
respond equally, and the inclusion of all analyzable coronary
segments in our study expands on the original observation of
El-Tamimi et al. (2) that not all areas of the artery respond equally.
As pointed out in our current study (1) as well as in our earlier
work (3), it is difficult to separate true physiologic heterogeneity
from methodologic variablity inherent in all analytic techniques.
We reiterate that the phenomenon of regression to the mean may
well account for some of the findings of most constricted and most
dilated segmental responses being moderated on follow-up. How-
ever, the conclusion that some responses are actually adversely
affected by lipid reduction cannot be made by our study given the
lack of a comparative placebo group—a more abnormal response
might be expected at follow-up given the natural history of
atherosclerotic coronary disease, and some of these “worsened”
responses could have been an improvement over that seen in the
absence of lipid reduction.
We agree that the pattern of vasomotor response and the
correlation with oxidized low-density lipoprotein may possibly
reflect a given patient’s clinical response to lipid-lowering therapy.
This observation deserves further study.
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Vascular Endothelial Growth Factor:
Angiogenesis, Atherogenesis or Both?
Vascular endothelial growth factor (VEGF), a specific mitogen for
endothelial cells, was initially regarded to be a remedy for impaired
reendothelialization of arteries in patients treated with balloon
angioplasty. Supplementation with VEGF was also expected to
induce the formation of blood vessels nourishing ischemic heart or
peripheral muscles.
Among the studies demonstrating the therapeutic efficiency of
VEGF were reports suggesting the opposite (1,2). It took, how-
ever, several years until stronger evidence was obtained. In recent
issues of JACC (1) and Nature Medicine (2) Celletti et al. (1,2) have
published data demonstrating that VEGF promotes atherogenesis.
They used two animal models: double knockout mice (apoE/
apoB100), in which spontaneous atherosclerosis was aggravated by
a single injection of a low dose of VEGF protein (2), and
cholesterol-fed rabbits, which when treated by VEGF developed
larger plaques (1,2). The investigators showed that VEGF in-
creased the total number of blood and plaque monocytes/
macrophages and enriched the pool of circulating CD34/flk1
progenitor cells that might enhance neoangiogenesis (1,2).
Those intriguing studies raise many questions. Particulary, it
remains to be established how those experimental data relate to the
results of the clinical trials with angiogenic growth factors, which
so far did not report any significant side effects. In our opinion the
results presented by Celletti et al. (1,2) force us also to reinvestigate
the role of VEGF using more basic approaches. One of the crucial
aims will be to understand the mechanisms governing VEGF
synthesis and angiogenic activity in normal and atherosclerotic
vessels.
We have recently demonstrated that nitric oxide (NO) enhanced
VEGF synthesis in vascular smooth muscle cells (VSMC) (3,4).
Nitric oxide synthesis is inhibited by modified low-density li-
poprotein (LDL), which is elevated in atherosclerosis (5). How-
ever, this does not result in attenuation of VEGF production. In
fact, lipid components of modified LDL enhanced VEGF expres-
sion in VSMC independently of their inhibitory effect on the
generation of NO by inducible nitric oxide synthase (iNOS) (5).
Those data, which are supported by others (6), show that
different factors can enhance VEGF in the vessel wall and initiate
or promote atherosclerosis. In fact, VEGF is strongly expressed in
the plaque (7,8). Thus, probably the inhibition, but not the
supplementation, of VEGF has to be regarded for the treatment of
atherosclerosis. Application of a strong antiangiogenic treatment
might not be a good option for patients with already impaired
blood supply and developing plaques. However, an interesting,
safer alternative might already exist. The statins, inhibitors of
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